Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Carcinomas: Case Series

#2163

Introduction: High-grade neuroendocrine carcinomas (NECs) possess inevitable tendencies to metastasise and hold poor prospects of survival. Patients with neuroendocrine tumours who progress after medical management can be treated with peptide receptor radionuclide therapy (PRRT), on the proviso that there is positive uptake on 68Ga-DOTATATE PET/CT imaging. Despite this, a proportion of patients who exhibit positive imaging respond poorly to therapy. Management of NECs is currently limited; evidence for treating NECs with PRRT is scarce.

Aim(s): We describe clinical efficacy and safety outcomes in a case series of 5 patients with advanced metastatic NEC treated with 177Lu-DOTATATE PRRT.

Materials and methods: A retrospective, single-centre analysis was conducted, whereby records of patients with NECs who received PRRT were reviewed. Complete biochemical parameters and disease features were captured and treatment outcomes were assessed.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Butt S, Evans J, Sharma R,

Keywords: neuroendocrine, carcinoma, tumours, PRRT,